Date: 2017-09-25
Type of
information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the American Society of Clinical Oncology (ASCO) annual meeting, in Chicago at the XIII Annual Meeting of the Oligonucleotide Therapeutics Society (OTS)
Company: Sylentis (Spain)
Product: SYL136001v10
Action
mechanism: RNAi/siRNA
Disease: neovascular diseases of the retina including age related macular degeneration (AMD)
Therapeutic
area: Ophtalmological diseases
Country:
Trial
details:
Latest
news:
- • On September 25, 2017, Sylentis has presented,data on the efficacy of SYL136001v10, a siRNA (small interference RNA) for the treatment of neovascular diseases of the retina such as Age-Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). SYL136001v10 reaches the retina when administered topically, demonstrating that the siRNA may be applied in eye drops changing the treatment paradigm for patients suffering these diseases. The data have been presented at the XIII Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) taking place in Bourdeaux, France.
- Sylentis has identified NRARP (NOTCH-regulated Ankyrin Repeat Protein) as a potential target for the treatment of angiogenic diseases of the retina. NRARP is a key regulator of the molecular pathways leading to vessel formation; as such, the consequences of modulating the expression of this gene with RNAi has been studied in animal models of retinal neovascularization.
- The results of the efficacy studies have shown that reduction of NRARP in the retina using RNAi leads to regression of neovascular lesions and that the lesion reductions observed are equivalent to those observed in response to anti-VEGF treatment, current standard treatment administered by intraocular injection.
Is
general: Yes
